Hospital Pharmacy Department, Uppsala University Hospital, Uppsala, Sweden.
Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
JAMA Netw Open. 2021 Apr 1;4(4):e216303. doi: 10.1001/jamanetworkopen.2021.6303.
Suboptimal use of medications is a leading cause of health care-related harm. Medication reviews improve medication use, but evidence of the possible benefit of inpatient medication review for hard clinical outcomes after discharge is scarce.
To study the effects of hospital-based comprehensive medication reviews (CMRs), including postdischarge follow-up of older patients' use of health care resources, compared with only hospital-based reviews and usual care.
DESIGN, SETTING, AND PARTICIPANTS: The Medication Reviews Bridging Healthcare trial is a cluster randomized crossover trial that was conducted in 8 wards with multiprofessional teams at 4 hospitals in Sweden from February 6, 2017, to October 19, 2018, with 12 months of follow-up completed December 6, 2019. The study was prespecified in the trial protocol. Outcome assessors were blinded to treatment allocation. In total, 2644 patients aged 65 years or older who had been admitted to 1 of the study wards for at least 1 day were included. Data from the modified intention-to-treat population were analyzed from December 10, 2019, to September 9, 2020.
Each ward participated in the trial for 6 consecutive 8-week periods. The wards were randomized to provide 1 of 3 treatments during each period: CMR, CMR plus postdischarge follow-up, and usual care without a clinical pharmacist.
The primary outcome measure was the incidence of unplanned hospital visits (admissions plus emergency department visits) within 12 months. Secondary outcomes included medication-related admissions, visits with primary care clinicians, time to first unplanned hospital visit, mortality, and costs of hospital-based care.
Of the 2644 participants, 7 withdrew after inclusion, leaving 2637 for analysis (1357 female [51.5%]; median age, 81 [interquartile range, 74-87] years; median number of medications, 9 [interquartile range, 5-13]). In the modified intention-to-treat analysis, 922 patients received CMR, 823 received CMR plus postdischarge follow-up, and 892 received usual care. The crude incidence rate of unplanned hospital visits was 1.77 per patient-year in the total study population. The primary outcome did not differ between the intervention groups and usual care (adjusted rate ratio, 1.04 [95% CI, 0.89-1.22] for CMR and 1.15 [95% CI, 0.98-1.34] for CMR plus postdischarge follow-up). However, CMR plus postdischarge follow-up was associated with an increased incidence of emergency department visits within 12 months (adjusted rate ratio, 1.29; 95% CI, 1.05-1.59) compared with usual care. There were no differences between treatment groups regarding other secondary outcomes.
In this study of older hospitalized patients, CMR plus postdischarge follow-up did not decrease the incidence of unplanned hospital visits. The findings do not support the performance of hospital-based CMRs as conducted in this trial. Alternative forms of medication reviews that aim to improve older patients' health outcomes should be considered and subjected to randomized clinical trials.
ClinicalTrials.gov Identifier: NCT02986425.
药物使用不当是导致医疗相关伤害的主要原因之一。药物审查可以改善药物使用情况,但关于出院后住院药物审查对硬临床结局的可能益处的证据很少。
研究医院为基础的综合药物审查(CMR)的效果,包括对老年患者出院后使用医疗资源的随访,与仅医院为基础的审查和常规护理进行比较。
设计、设置和参与者:药物审查桥接医疗试验是一项集群随机交叉试验,于 2017 年 2 月 6 日至 2018 年 10 月 19 日在瑞典的 4 家医院的 8 个病房中进行,为期 12 个月的随访于 2019 年 12 月 6 日完成。研究在试验方案中预先指定。结局评估者对治疗分配不知情。共有 2644 名年龄在 65 岁或以上的患者被纳入研究,这些患者在研究病房至少住院 1 天。从 2019 年 12 月 10 日至 2020 年 9 月 9 日对修改后的意向治疗人群进行了数据分析。
每个病房连续参与了 6 个为期 8 周的试验期。病房被随机分配在每个时期提供 3 种治疗方法之一:CMR、CMR 加出院后随访和没有临床药剂师的常规护理。
主要结局指标是 12 个月内无计划的医院就诊(入院和急诊就诊)的发生率。次要结局包括药物相关入院、初级保健临床医生就诊、首次无计划医院就诊时间、死亡率和医院为基础的护理成本。
在 2644 名参与者中,7 名在纳入后退出,2637 名进入分析(女性 1357 名[51.5%];中位年龄 81 [四分位间距,74-87]岁;中位数用药数 9 [四分位间距,5-13])。在修改后的意向治疗分析中,922 名患者接受了 CMR,823 名接受了 CMR 加出院后随访,892 名接受了常规护理。总研究人群中无计划医院就诊的粗发生率为 1.77 例/患者年。干预组与常规护理之间的主要结局没有差异(CMR 的调整后发生率比为 1.04[95%CI,0.89-1.22],CMR 加出院后随访的调整后发生率比为 1.15[95%CI,0.98-1.34])。然而,与常规护理相比,CMR 加出院后随访与 12 个月内急诊就诊的发生率增加有关(调整后发生率比为 1.29;95%CI,1.05-1.59)。在其他次要结局方面,治疗组之间没有差异。
在这项对老年住院患者的研究中,CMR 加出院后随访并未降低无计划的医院就诊发生率。研究结果不支持进行这项试验中所进行的基于医院的 CMR。应考虑并进行随机临床试验,以寻找旨在改善老年患者健康结局的替代药物审查形式。
ClinicalTrials.gov 标识符:NCT02986425。